Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2010 1
2019 1
2020 3
2021 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Prat A, et al. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Villacampa G, Falato C, Paré L, Hernando C, Arumí M, Saura C, Gómez G, Muñoz M, Gil-Gil M, Izarzugaza Y, Ferrer N, Najera-Zuloaga J, Montaño A, Ciruelos E, González-Santiago S, Villagrasa P, Gavilá J, Prat A, Pascual T. Villacampa G, et al. Eur J Cancer. 2022 Oct;174:232-242. doi: 10.1016/j.ejca.2022.07.028. Epub 2022 Sep 5. Eur J Cancer. 2022. PMID: 36067616 Clinical Trial.
Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients.
Mazuecos A, Villanego F, Zarraga S, López V, Oppenheimer F, Llinàs-Mallol L, Hernández AM, Rivas A, Ruiz-Fuentes MC, Toapanta NG, Jiménez C, Cabello S, Beneyto I, Aladrén MJ, Rodríguez-Benot A, Canal C, Molina M, Pérez-Flores I, Saura IM, Gavela E, Franco A, Lorenzo I, Galeano C, Tabernero G, Pérez-Tamajón L, Martín-Moreno PL, Fernández-Girón F, Siverio O, Labrador PJ, De Arriba G, Simal F, Cruzado L, Moina I, Alcalde G, Sánchez-Álvarez E, Pascual J, Crespo M; Spanish Society of Nephrology COVID-19 Group. Mazuecos A, et al. Transplantation. 2022 Jul 1;106(7):1430-1439. doi: 10.1097/TP.0000000000004119. Epub 2022 Apr 1. Transplantation. 2022. PMID: 35384924 Free PMC article.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
Llombart-Cussac A, Pérez-Garcia JM, Ruiz Borrego M, Tolosa P, Blanch S, Fernández-Ortega A, Urruticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce Lorenzo J, Gion M, Cortez-Castedo P, Llabres E, Galve E, Cueva JF, López A, Alonso-Romero JL, González-Santiago S, Martínez de Dueñas E, Ciruelos E, Martrat G, Gener P, Alcalá-López D, Sampayo-Cordero M, Gómez-Peralta F, Cortés J. Llombart-Cussac A, et al. EClinicalMedicine. 2024 Apr 11;71:102520. doi: 10.1016/j.eclinm.2024.102520. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38638399 Free PMC article.
Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S, Saura C, Ciruelos E, Alonso JL, de la Morena P, Santisteban Eslava M, Gallegos Sancho MI, de Luna A, Dalmau E, Servitja S, Ruiz Borrego M, Chacón JI. González-Santiago S, et al. Breast Cancer Res Treat. 2020 Nov;184(2):469-479. doi: 10.1007/s10549-020-05866-1. Epub 2020 Sep 2. Breast Cancer Res Treat. 2020. PMID: 32876911
Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: Results of the IBERICAN study.
Llisterri JL, Micó-Pérez RM, Velilla-Zancada S, Rodríguez-Roca GC, Prieto-Díaz MÁ, Martín-Sánchez V, Barquilla A, Polo-García J, Segura-Fragoso A, Cinza-Sanjurjo S; en representación de los investigadores del estudio IBERICAN y de la Fundación de la Sociedad Española de Médicos de Atención Primaria (SEMERGEN); Listado de investigadores del estudio IBERICAN. Comité científico; Andalucía; Aragón; Cantabria; Castilla La Mancha; Castilla y León; Cataluña; Comunidad de Madrid; Comunidad Valenciana; Extremadura; Galicia; Islas Baleares; Islas Canarias; La Rioja; Melilla; Navarra; País Vasco; Principado de Asturias; Región de Murcia. Llisterri JL, et al. Med Clin (Barc). 2021 Feb 26;156(4):157-165. doi: 10.1016/j.medcli.2020.03.005. Epub 2020 May 12. Med Clin (Barc). 2021. PMID: 32414634 English, Spanish.